Itulazax (Betula Verrucosa (108))

Betula verrucosa extract in Itulazax works by repeatedly presenting the birch pollen allergen to the immune system via the sublingual route. This exposure promotes the development of regulatory T‑cells and shifts the immune response away from IgE‑driven allergy toward a more tolerant phenotype, thereby decreasing mast‑cell activation and symptom severity during pollen season.

The dosing regimen for Itulazax is individualized and set by the prescribing physician based on the patient’s age, severity of allergy, and response to treatment. The prescriber determines the starting concentration, escalation schedule, and maintenance dose, which are adjusted during follow‑up visits to achieve optimal clinical benefit.

Safety data for Itulazax in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers are advised to discuss the lack of definitive safety information with pregnant or nursing patients before initiating therapy.

To order Itulazax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Itulazax offers a sublingual route, which can be more convenient and avoids injections required for subcutaneous immunotherapy (SCIT). Sublingual administration allows patients to self‑dose at home after the initial supervised dose, while still achieving comparable long‑term tolerance. However, individual response varies, and the choice between sublingual and injectable forms depends on patient preference, adherence, and clinical considerations.

Itulazax should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperature fluctuations. Do not refrigerate or freeze unless the manufacturer’s packaging specifically indicates a cold‑chain requirement.

Itulazax is administered sublingually. The patient places the prescribed dose under the tongue, holds it for the time indicated by the prescriber (typically 1–2 minutes), and then swallows. No water or food should be taken for at least 15 minutes after dosing to ensure optimal absorption.

The most serious risks include systemic allergic reactions such as anaphylaxis, angioedema, and severe bronchospasm. These events, although rare, require immediate medical attention. Patients should be educated to recognize early signs of a severe reaction and to seek emergency care promptly if symptoms develop.

Itulazax is contraindicated in individuals with a history of severe anaphylactic reaction to birch pollen, uncontrolled asthma, or other severe uncontrolled allergic diseases. Patients currently receiving other allergen immunotherapies without specialist guidance should also avoid using Itulazax until a thorough risk assessment is performed.